BioGenes takes Host Cell Protein, Immunogenicity and PK Testing Solutions to Chinese Markets

Berlin, Germany: – Leading force in host cell protein (HCP) assay development, BioGenes GmbH is extending its reach to China, presenting its innovative immunogenicity and pharmacokinetic (PK) testing tools at an influential partnering conference near Shanghai.

BioGenes is attending for the first time at the 10th ChinaBIO partnering forum in Suzhou, networking with more than 1,000 decision makers representing more than 400 companies, the majority of them from China.

The company will be represented by the BioGenes` Marketing/Sales Manager Dr. Marieke Mohr.

She will be presenting a wide range of solutions that include custom ELISA development and kit production for HCP, immunogenicity and PK testing solutions including custom antibody development (pAbs, mAbs, anti-IDs).

“We believe that attending ChinaBIO is an effective way of nurturing new business contacts, partners and clients in Asia, and the rapidly expanding Chinese market in particular,” said Ms. Dagmar Schwertner-Knoll, Marketing/Sales Director.

ELISA analytics

“It provides a great platform to present our highly innovative and effective services for ELISA development and analytics and finding distribution partners for our ELISA kits (in China?),” she explained.

“It will also provide a great forum to share new developments in the testing of new therapeutics and biosimilars,” Ms. Schwertner-Knoll added.

“We believe ChinaBIO will put us in touch with an expanding Chinese and Asian user base of biotech and pharma companies developing and producing new therapeutic biologics or biosimilars and performing PK or Immunogenicity studies,” said Dr. Marieke Mohr.

About BioGenes GmbH

BioGenes GmbH (BioGenes) is an acknowledged global leader in host cell protein (HCP) assay development and a recognized partner of pharmaceutical companies all over the world. The Berlin-based company specializes in highly sophisticated and customized antibody and immunoassay development and is an experienced and reliable partner for process development improvements in all areas of quality control, diagnostics and drug discovery.

BioGenes is known as a trusted and experienced expert in immunoassay, 2D electrophoresis and antibody development with a business strategy focused on driving forward innovations for customers and building new strategic partnerships aimed at cementing its market leadership in host cell assay development.

BioGenes was founded in 1992 by Dr. Alexander Knoll (Managing Director) and Dr. Sergej Ovodov (Scientific Director), who are now sole owners following a management buyout in October 2015. Headquartered in Berlin, the company has a workforce numbering more than 50 people, most of them scientists.

The company maintains long-term relationships with research institutes, universities and biotech and pharmaceutical companies, including eight of the ten largest pharmaceutical companies in the world.

About ChinaBIO 2018

Founded in 2008, the annual ChinaBIO Partnering Forum is from the same stable as the BIO-Europe series and BIOPharm America and is a networking, partnering and knowledge sharing conference for pharmaceutical and venture capital decision makers.

ChinaBIO 2018is a two-day event opening April 25 at the Kempinski Hotel, Suzhou, northwest of Shanghai that will include more than 50 keynote speeches and company presentations, along with an estimated 1.600 web-facilitated one-to-one partnering meetings.

It is expected to attract more than 1,000 delegates representing some 450 companies, around 70 per cent of them from China.

The event is jointly organised by EBD Group and ChinaBIO with further information at: https://ebdgroup.knect365.com/chinabio-partnering/.